Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Ontology highlight
ABSTRACT: Regulatory agencies have concluded that sodium glucose cotransporter 2 (SGLT2) inhibitors lead to ketoacidosis, but published literature on this point remains controversial. We searched the FDA Adverse Event Reporting System (FAERS) for reports of acidosis in patients treated with canagliflozin, dapagliflozin, or empagliflozin (from the date of each drug's FDA approval until May 15, 2015). We compared the number of SGLT2 inhibitor-related reports to reports of acidosis in patients treated with the 2 most commonly used DPP4 inhibitors: sitagliptin and saxagliptin. We estimated relative risks of acidosis by relating the number of reports to cumulative drug sales (a surrogate for patient exposure). FAERS contained 259 reports of acidosis (including 192 reports of ketoacidosis) for SGLT2 inhib
SUBMITTER: Blau JE
PROVIDER: S-EPMC5950709 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA